The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.

Verismo’s SynKIR-310 posts 80% response rate in lymphoma interim data

Nov 5, 2026 02:06 (6h ago)

Verifying

Verismo Therapeutics reported interim results for SynKIR-310 in B-cell non-Hodgkin lymphoma.
SynKIR-310 recorded an 80% objective response rate and 60% complete response rate.
The therapy targets patients with relapsed or refractory disease, according to Verismo.